Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in Cardiomyopathy

 

• Alnylam Pharmaceuticals' Phase 3 HELIOS-B trial reveals significant results for Amvuttra in reducing mortality for ATTR amyloidosis patients.
• Analyst price targets for ALNY suggest a potential 13.51% upside from its current price.
• GuruFocus estimates indicate a potential 46.05% upside based on GF Value projections.

Alnylam Pharmaceuticals (ALNY, Financial) has made a significant stride with its RNAi therapy, Amvuttra (vutrisiran). In the recent Phase 3 HELIOS-B trial, Amvuttra demonstrated a substantial 36% reduction in all-cause mortality among patients suffering from ATTR amyloidosis and cardiomyopathy over a 42-month period when compared to placebo treatments. This promising outcome could potentially elevate Alnylam's presence in the pharmaceutical market.

https://www.gurufocus.com/news/2872049/alnylam-alny-reports-positive-longterm-data-for-amvuttra-in-cardiomyopathy-trial